<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03947879</url>
  </required_header>
  <id_info>
    <org_study_id>2018-119</org_study_id>
    <nct_id>NCT03947879</nct_id>
  </id_info>
  <brief_title>The Effect of Pharmaceutical Grade L-glutamine (Endari) on Glycemic Control in Patients With Diabetes Mellitus Type II</brief_title>
  <official_title>The Effect of Pharmaceutical Grade L-glutamine (Endari) on Glycemic Control in Patients With Diabetes Mellitus Type II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hawaii Pacific Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hawaii Pacific Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an initial non-blinded, non-placebo controlled trial to determine the efficacy
      of L-glutamine in lowering blood sugar in patients with diabetes mellitus type II without
      sickle cell anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol will consist of starting patients on 15 g of L glutamine twice daily by mouth.
      This is the same dose that is used to treat patient with sickle cell anemia. They will be
      given this medication for a total of 3 months. Their other medications will remain the same.
      At the conclusion of the 3 months, the patients will be taken off of the glutamine and will
      continue their other medications. The investigators will monitor the patients an additional 3
      months (6 months after the initiation of the study) off the L-glutamine. In this manner, the
      investigators will have a washout period. The outcome will be a comparison of the results
      before the initiation of the L-glutamine, to the results after treatment, and after the
      washout.

      Data analysis will consist of comparing the patient's fasting glucose and hemoglobin A1c
      values. The investigators will also check the levels of fructosamine. This is a standard test
      that is done in any clinical laboratory. To help determine the mechanism for the L-glutamine
      effect, the investigators will also measure the complete blood count, chemistry panel,
      hepatic function panel, urine micro-albumin, patients' weight, and waist circumference. The
      investigators will use the Student t-test for statistical analysis. Significance will be
      tested at the 0.05 level.

      The investigators will collect demographic information on the patients in the study. Age,
      sex, duration of diabetes, smoking history, and race will be noted. The investigators will
      use regression analysis to determine whether these factors have any effects on the observed
      results.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fasting glucose</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in fasting glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hemoglobin A1c</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in hemoglobin A1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fructosamine</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in fructosamine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in complete blood count</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in complete blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood chemistry</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in blood chemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hepatic function</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Chang e in hepatic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microablbumin</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in urine microalbumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in waist circumference</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>L-glutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with L-glutamine for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No L-glutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No L-glutamine for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-glutamine</intervention_name>
    <description>15 g of L-glutamine twice daily by mouth for 3 months.</description>
    <arm_group_label>L-glutamine</arm_group_label>
    <other_name>Endari</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No L-glutamine</intervention_name>
    <description>The same patients will be given no L-glutamine for 3 months.</description>
    <arm_group_label>No L-glutamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of diabetes mellitus type II

          -  Patient of Straub Medical Center, Internal Medicine Clinic

        Exclusion Criteria:

          -  Renal and liver impairment ( GFR less than 40)

          -  Transaminitis (elevation of AST of ALT more than 2 fold)

          -  Patient with sickle cell anemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Zerez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Straub Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Zerez, MD, PhD</last_name>
    <phone>808-522-4000</phone>
    <email>czerez@straub.net</email>
  </overall_contact>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>May 10, 2019</last_update_submitted>
  <last_update_submitted_qc>May 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hawaii Pacific Health</investigator_affiliation>
    <investigator_full_name>Charles R Zerez, PhD, MD</investigator_full_name>
    <investigator_title>Internal Medicine Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

